HUE070621T2 - Nalmefén alkoholfogyasztás csökkentésére specifikus célpopulációkban - Google Patents

Nalmefén alkoholfogyasztás csökkentésére specifikus célpopulációkban

Info

Publication number
HUE070621T2
HUE070621T2 HUE23163177A HUE23163177A HUE070621T2 HU E070621 T2 HUE070621 T2 HU E070621T2 HU E23163177 A HUE23163177 A HU E23163177A HU E23163177 A HUE23163177 A HU E23163177A HU E070621 T2 HUE070621 T2 HU E070621T2
Authority
HU
Hungary
Prior art keywords
nalmefene
reduction
specific target
alcohol consumption
target populations
Prior art date
Application number
HUE23163177A
Other languages
English (en)
Hungarian (hu)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladstroem
Christine Persson
Didier Meulien
Per Sorensen
Thomas Jensen
Jette Ostergaard
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE070621(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HUE070621T2 publication Critical patent/HUE070621T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HUE23163177A 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célpopulációkban HUE070621T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE070621T2 true HUE070621T2 (hu) 2025-06-28

Family

ID=48703496

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE23163177A HUE070621T2 (hu) 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célpopulációkban
HUE17206034A HUE063313T2 (hu) 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célcsoportok esetében
HUE16187426A HUE036272T2 (hu) 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célcsoportok esetében
HUE13732471A HUE031110T2 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE17206034A HUE063313T2 (hu) 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célcsoportok esetében
HUE16187426A HUE036272T2 (hu) 2012-06-27 2013-06-27 Nalmefén alkoholfogyasztás csökkentésére specifikus célcsoportok esetében
HUE13732471A HUE031110T2 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP3138564B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3345604T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2609122T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20250329T1 (enExample)
HU (4) HUE070621T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3138564T (enExample)
ME (2) ME02587B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT2866808T (enExample)
RS (2) RS55456B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI2866808T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
AU2015250611A1 (en) 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CN102459276B (zh) 2009-05-25 2016-09-21 H.隆德贝克有限公司 从纳曲酮制备盐酸纳美芬
CA2815093C (en) 2010-11-05 2019-08-06 H. Lundbeck A/S Method for the manufacturing of naltrexone
JP5738470B2 (ja) 2011-03-31 2015-06-24 イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア．シェ．Ｉｍｕｎｅｋｓ Ｆａｒｍａ Ｉｌａｃ Ｓａｎａｙｉ Ｖｅ Ｔｉｃａｒｅｔ Ａ．Ｓ． オピオイド拮抗体組成物、および強皮症の治療のためのその使用
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
HRP20230762T8 (hr) 2024-01-05
SMT201600471T1 (it) 2017-03-08
HUE036272T2 (hu) 2018-06-28
US9642849B2 (en) 2017-05-09
EA029908B1 (ru) 2018-05-31
EP2866808A1 (en) 2015-05-06
ZA201409525B (en) 2016-08-31
EP4223296A3 (en) 2023-09-27
JP2019163275A (ja) 2019-09-26
SMT201600471B (it) 2017-03-08
HK1255683A1 (en) 2019-08-23
MX2014015488A (es) 2015-03-06
LT3138564T (lt) 2018-04-10
EA201492152A1 (ru) 2015-11-30
PT3138564T (pt) 2018-04-03
ES2663532T3 (es) 2018-04-13
SMT201800164T1 (it) 2018-07-17
US10034874B2 (en) 2018-07-31
EP4541421A2 (en) 2025-04-23
SG11201408704WA (en) 2015-01-29
EP3345604B1 (en) 2023-06-07
CL2014003484A1 (es) 2015-02-27
US20140005216A1 (en) 2014-01-02
DK3138564T3 (en) 2018-03-26
ES3014068T3 (en) 2025-04-16
ES2609122T3 (es) 2017-04-18
HRP20180363T1 (hr) 2018-04-20
LT2866808T (lt) 2017-01-10
CO7160087A2 (es) 2015-01-15
IL236035B (en) 2018-12-31
NZ702191A (en) 2017-06-30
DK2866808T3 (en) 2017-01-16
RS57046B1 (sr) 2018-05-31
DK3345604T3 (da) 2023-07-24
IL236035A0 (en) 2015-01-29
CY1118579T1 (el) 2017-07-12
PT3345604T (pt) 2023-07-17
UA114199C2 (uk) 2017-05-10
ME03030B (me) 2018-10-20
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
PT2866808T (pt) 2017-01-03
CA2874703A1 (en) 2014-01-03
KR20150023396A (ko) 2015-03-05
JP2018039810A (ja) 2018-03-15
PL4223296T3 (pl) 2025-04-14
WO2014001427A1 (en) 2014-01-03
PL3345604T3 (pl) 2023-08-28
ES2950492T3 (es) 2023-10-10
MX371373B (es) 2020-01-28
AU2013283281B2 (en) 2017-04-20
HK1208185A1 (en) 2016-02-26
SI3345604T1 (sl) 2023-08-31
MY166914A (en) 2018-07-24
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
JP6258933B2 (ja) 2018-01-10
EP3345604A1 (en) 2018-07-11
ME02587B (me) 2017-06-20
EP3138564B1 (en) 2018-01-31
CY1126140T1 (el) 2023-11-15
BR112014032555A2 (pt) 2017-06-27
EP4223296A2 (en) 2023-08-09
HRP20230762T1 (hr) 2023-10-13
CY1120097T1 (el) 2018-12-12
LT3345604T (lt) 2023-08-10
HRP20161717T1 (hr) 2017-02-10
JP2015521647A (ja) 2015-07-30
PL2866808T3 (pl) 2017-04-28
CA2874703C (en) 2022-08-23
EP4223296C0 (en) 2025-01-29
SI3138564T1 (en) 2018-04-30
FI3345604T3 (fi) 2023-07-28
CN104411313A (zh) 2015-03-11
US20140005217A1 (en) 2014-01-02
EP4223296B1 (en) 2025-01-29
HUE031110T2 (en) 2017-06-28
HRP20250329T1 (hr) 2025-05-09
RS55456B1 (sr) 2017-04-28
HUE063313T2 (hu) 2024-01-28
EP2866808B1 (en) 2016-11-02
AU2013283281A1 (en) 2014-12-11
EP4541421A3 (en) 2025-06-18
EP3138564A1 (en) 2017-03-08
PL3138564T3 (pl) 2018-06-29
RU2014151156A (ru) 2016-08-20
JP6857684B2 (ja) 2021-04-14
US20180028526A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL236525A0 (en) Antibodies against conserved targets
IL236625B (en) Processes for preparing derivatives of 3-carbonyl-4-hydroxy-isoquinoline and intermediates obtained in these processes
PT2748562T (pt) Identificação de consumos de serviços
GB201222625D0 (en) Improvements relating to tracking moving objects
GB201501116D0 (en) Improvements to refrigeration systems
ZA201409525B (en) Nalmefene for reduction of alcohol consumption in specific target populations
GB2505638B (en) Continuous culture
EP2591368A4 (en) METHOD FOR DETERMINING ETHANOL CONSUMPTION
GB2492873B (en) Soap Saving system
EP2845186A4 (en) EFFECTIVE ANTICRENELING IN ENERGY
EP2702462A4 (en) UNAUVIKED WAKING UP
GB201214566D0 (en) Improvements in and relating to virtualised systems
GB201114034D0 (en) Ashiur ayana ayana woman
GB201012404D0 (en) Taxi beeper
GB201110463D0 (en) Energy-efficient device
GB201222657D0 (en) Improvements relating to personal tracking identifiers
GB201108369D0 (en) Utility columns
AU338684S (en) Bolero
GB201102831D0 (en) Follicle culture
AU2011036V (en) DC1000 Dianella caerulea
AU2011037V (en) DC2100 Dianella caerulea
AU2011038V (en) DC4000 Dianella caerulea
AU2011039V (en) DC6000 Dianella caerulea